Adnan Ameer, MD
Gastroenterology · Fallbrook
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
- Since medical school
- 17 years
- Graduated 2009
Offices
1 location · United Medical Doctors · 168 clinicians in this group
Hospitals listed: Providence Little Company of Mary Med Ctr Torrance · Torrance Memorial Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Ameer’s office at (760) 728-9560 to ask if they take your plan before you enroll.
California Medical Board record
Licence A118254 · Current
Licensed to practise in California · since 2011 · expires 2027-09-30 · Ross University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Internal Medicine - Gastroenterology
- American Board of Internal Medicine - Internal Medicine
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Providence Little Company of Mary Med Ctr TorranceTorrance, CAAcute Care Hospital · Voluntary non-profit - Church · No emergency department · Birthing-friendlyPart of Providence, which runs 54 hospitals in 7 statesPatients rate it 3 of 5 · 70% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.472, Oct 2024 – Sep 2025
- Torrance Memorial Medical CenterTorrance, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of Cedars Sinai Health System, which runs 4 hospitalsPatients rate it 3 of 5 · 82% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — CMS Medicare PSI 90: Patient safety and adverse events composite: 1.36 (1.11 to 1.61), Jul 2022 – Jun 2024Worse than the national rate — Postoperative respiratory failure rate: 15.79 (10.51 to 21.07) · 1,494 cases, Jul 2022 – Jun 2024Worse than the national rate — Pressure ulcer rate: 1.21 (0.72 to 1.71) · 9,154 cases, Jul 2022 – Jun 2024Better than the national rate — Clostridium Difficile (C.Diff): 0.328, Oct 2024 – Sep 2025
See every measure and the patient survey for Providence Little Company of Mary Med Ctr Torrance
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 0 better, 8 the same, 1 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.472 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.09 (0.11 to 2.07) · 1,022 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.9 (0.59 to 1.2) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 129.31 (75.73 to 182.88) · 65 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2 · 36 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 10.3 · 70 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11 · 141 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.4 · 353 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.2 · 361 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.5 · 495 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.4 · 3,150 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.19 (0 to 0.39) · 5,786 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.25 (0.06 to 0.45) · 5,832 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.21 (2.1 to 6.32) · 1,135 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.81 (0.22 to 3.4) · 375 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.33 (0.8 to 3.86) · 1,086 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.78 (2.28 to 15.28) · 389 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.58 (1.19 to 7.98) · 377 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2 (0.51 to 3.49) · 247 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.3 (0 to 0.93) · 4,918 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.9 · 127 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.892 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.225 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.363 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.7 · 283 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22 · 709 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 10.5 · 149 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 7.9 · 428 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -13.8 · 369 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.6 · 551 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 130 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.7 · 59 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 168 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 11.8 (8.9 to 15.5) · 642 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.3) · 331 cases | No different | Jan 2024 – Dec 2024 |
What patients said (414 patients answered, 18% of those asked)
| Cleanliness | 3 |
| Nurse communication | 4 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 69% |
| Nurses "always" communicated well | 78% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 60% |
| Yes, staff "did" give patients this information | 85% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 81% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 74% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 85% |
| "Always" quiet at night | 45% |
| "YES", patients would definitely recommend the hospital | 70% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 84% |
See every measure and the patient survey for Torrance Memorial Medical Center
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 4 the same, 1 worse of 8 measures. Readmissions: 0 better, 8 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.36 (1.11 to 1.61) | Worse | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 15.79 (10.51 to 21.07) · 1,494 cases | Worse | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 1.21 (0.72 to 1.71) · 9,154 cases | Worse | Jul 2022 – Jun 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.328 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.85 (0 to 1.72) · 2,154 cases | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 171.72 (128.91 to 214.54) · 121 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.2 · 36 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8 · 136 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.3 · 176 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 7.8 · 766 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 12.4 · 806 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.5 · 608 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.8 · 7,587 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.28 (0.1 to 0.47) · 11,109 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.03 to 0.39) · 11,330 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.13 (2.41 to 5.85) · 2,964 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.64 (0.13 to 3.16) · 1,513 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.66 (1.3 to 4.01) · 2,802 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.24 (2.35 to 8.14) · 1,479 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.55 (0.11 to 2.98) · 650 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 2 · 962 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.023 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.646 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.751 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 1.259 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.658 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.1 · 300 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.2 · 1,578 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 21.1 · 183 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 1.5 · 900 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 27.9 · 800 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19.1 · 1,223 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.3 (3.3 to 8.3) · 26 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.5 (7 to 15) · 26 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 928 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12 · 65 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21 · 316 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.3 (9.5 to 16.1) · 624 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 781 cases | No different | Jan 2024 – Dec 2024 |
What patients said (2,607 patients answered, 26% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 74% |
| Nurses "always" communicated well | 78% |
| Doctors "always" communicated well | 78% |
| Staff "always" explained | 59% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 83% |
| Doctors "always" explained things so they could understand | 73% |
| Doctors "always" listened carefully | 77% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 78% |
| Staff "always" explained new medications | 73% |
| Nurses "always" explained things so they could understand | 74% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 85% |
| "Always" quiet at night | 51% |
| "YES", patients would definitely recommend the hospital | 82% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$38,388
Medicare paid this office $38,388 for 145 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 78 | $8,737 | $108 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 54 | $4,826 | $65 |
| Biopsy of large bowel using a flexible endoscope | 23 | $2,951 | $128 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 33 | $2,820 | $81 |
| New patient visit (45+ min) | 18 | $2,441 | $136 |
See all 11 services
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 78 | $8,737 | $108 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 54 | $4,826 | $65 |
| Biopsy of large bowel using a flexible endoscope | 23 | $2,951 | $128 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 33 | $2,820 | $81 |
| New patient visit (45+ min) | 18 | $2,441 | $136 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 11 | $2,423 | $220 |
| Return visit (30+ min) | 14 | $2,105 | $111 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 16 | $1,460 | $86 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 11 | $1,275 | $98 |
| New patient visit (30+ min) | 12 | $1,152 | $96 |
| Short return visit (20+ min) | 11 | $946 | $79 |
Procedures Medicare counted
| Colonoscopy | 39 | More than 59% of doctors who do this |
| Upper gastrointestinal (GI) endoscopy for acid reflux | 80 | More than 72% of doctors who do this |
Procedures year by year
| Procedure | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 73 | 133 | 133 | 68 | 75 | 35 |
| Biopsy of large bowel using a flexible endoscope | 29 | 45 | 53 | 28 | 64 | 23 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 38 | 43 | 59 | – | – | 17 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 20 | 18 | 28 | 24 | 35 | 11 |
| Diagnostic exam of large bowel using a flexible endoscope | 11 | 21 | 31 | 14 | – | – |
| Ultrasound exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | – | 30 | 25 | 12 | – | – |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
145 Original Medicare patients in 2024. Average age 75 · Under 65 12% · 85 and older 23% · Women 58% · Also on Medicaid 88% · Health risk score 3.30. Sicker patients than 9 in 10 peers; the typical gastroenterology clinician is at 1.42.
Conditions among them: High blood pressure 75% · Diabetes 70% · Chronic kidney disease 54% · Coronary heart disease 50% · Heart failure 45% · Depression 33% · COPD 30% · Atrial fibrillation 29% · Dementia 28% · Stroke 27% · Cancer 19%.
The office billed $222,798, Medicare allowed $47,802 and paid $38,388; for 366 services of 29 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 145 | 366 | 75 | 3.30 | $222,798 | $38,388 |
| 2023 | 267 | 658 | 71 | 1.30 | $314,360 | $67,079 |
| 2022 | 133 | 398 | 75 | 1.12 | $134,657 | $48,132 |
| 2021 | 391 | 907 | 70 | 2.75 | $472,775 | $104,235 |
| 2020 | 367 | 892 | 70 | 2.59 | $443,193 | $102,629 |
| 2019 | 293 | 642 | 70 | 2.79 | $285,936 | $73,947 |
| 2018 | 121 | 331 | 76 | 2.01 | $101,466 | $40,930 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 12 services
| Telephone medical discussion with physician, 21-30 minutes | 74 | $8,979 | $100 |
| Biopsy of large bowel using a flexible endoscope | 64 | $7,642 | $119 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 35 | $7,238 | $207 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 75 | $5,760 | $77 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 38 | $5,717 | $147 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 19 | $3,680 | $194 |
| New patient visit (45+ min) | 32 | $2,998 | $94 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 22 | $2,716 | $101 |
| Ultrasound exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope through mouth | 14 | $2,220 | $159 |
| Telephone medical discussion with physician, 11-20 minutes | 22 | $1,602 | $73 |
| Return visit (30+ min) | 19 | $1,411 | $64 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 105 | $478 | $4 |
2022: 9 services
| New patient visit (45+ min) | 82 | $10,864 | $132 |
| Return visit (30+ min) | 62 | $10,171 | $109 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 65 | $5,411 | $80 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 24 | $4,966 | $207 |
| Biopsy of large bowel using a flexible endoscope | 25 | $3,456 | $123 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 14 | $2,698 | $193 |
| Ultrasound exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 12 | $2,141 | $178 |
| Diagnostic exam of large bowel using a flexible endoscope | 14 | $2,034 | $145 |
| New patient visit (30+ min) | 15 | $1,181 | $79 |
2021: 18 services
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 113 | $12,456 | $110 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 126 | $10,365 | $78 |
| Insertion of stent into pancreatic or bile duct using a flexible endoscope | 20 | $8,422 | $337 |
| Biopsy of large bowel using a flexible endoscope | 53 | $6,383 | $120 |
| Return visit (30+ min) | 47 | $5,934 | $104 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 28 | $5,841 | $209 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 30 | $5,189 | $162 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 58 | $5,028 | $85 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 39 | $4,831 | $83 |
| Ultrasound exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 25 | $4,675 | $187 |
| Ultrasound guided needle aspiration or biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 18 | $3,911 | $206 |
| Diagnostic exam of large bowel using a flexible endoscope | 30 | $3,786 | $122 |
| Long return visit (40+ min) | 19 | $3,033 | $132 |
| New patient visit (45+ min) | 23 | $2,749 | $120 |
| Control of bleeding of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 13 | $2,300 | $164 |
| Removal of stone or debris from bile or pancreatic duct using a flexible endoscope | 20 | $1,100 | $34 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 25 | $914 | $32 |
| Review by radiologist of image from tube placement into bile duct using an endoscope | 21 | $810 | $24 |
2020: 18 services
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 115 | $13,317 | $113 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 123 | $10,121 | $76 |
| Insertion of stent into pancreatic or bile duct using a flexible endoscope | 18 | $6,787 | $357 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 55 | $6,635 | $86 |
| Long return visit (40+ min) | 45 | $6,445 | $117 |
| Biopsy of large bowel using a flexible endoscope | 44 | $5,459 | $121 |
| Ultrasound exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 29 | $5,093 | $170 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 28 | $4,839 | $167 |
| Return visit (30+ min) | 40 | $4,274 | $79 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 41 | $4,191 | $97 |
| Ultrasound guided needle aspiration or biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 17 | $4,100 | $216 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 17 | $3,670 | $204 |
| Diagnostic exam of large bowel using a flexible endoscope | 21 | $3,236 | $154 |
| Removal of stent from pancreatic or bile duct using a flexible endoscope | 11 | $3,198 | $291 |
| New patient visit (45+ min) | 22 | $2,449 | $111 |
| Removal of stone or debris from bile or pancreatic duct using a flexible endoscope | 17 | $1,030 | $34 |
| Review by radiologist of image from tube placement into bile duct using an endoscope | 17 | $830 | $30 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 16 | $616 | $32 |
2019: 13 services
| New patient visit (45+ min) | 49 | $6,463 | $132 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 53 | $5,844 | $110 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 70 | $5,542 | $76 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 26 | $4,557 | $169 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 20 | $4,219 | $211 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 37 | $4,089 | $61 |
| Return visit (30+ min) | 41 | $4,010 | $87 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 37 | $3,569 | $94 |
| Biopsy of large bowel using a flexible endoscope | 29 | $3,287 | $113 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 27 | $2,888 | $85 |
| Long return visit (40+ min) | 20 | $2,132 | $107 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 24 | $1,927 | $80 |
| Diagnostic exam of large bowel using a flexible endoscope | 11 | $1,620 | $147 |
2018: 6 services
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 62 | $10,693 | $170 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 46 | $5,388 | $61 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 30 | $2,897 | $97 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 27 | $2,838 | $89 |
| Biopsy of large bowel using a flexible endoscope | 15 | $2,325 | $155 |
| Long return visit (40+ min) | 13 | $1,769 | $126 |
Medicaid work
$86,504 in 2024
Medicaid paid $86,504 for 2,244 billed services this clinician did in 2024, up to 34 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Service | 194 | $22,412 |
| TISSUE EXAM BY PATHOLOGIST | 176 | $12,354 |
| COLONOSCOPY AND BIOPSY | 129 | $9,452 |
| Clinic visit/encounter, all-inclusive | 47 | $8,816 |
| Upper gastrointestinal endoscopy with biopsy | 102 | $6,087 |
| New patient visit (45+ min) | 77 | $5,470 |
| New patient visit (30+ min) | 140 | $4,038 |
| Return visit (30+ min) | 57 | $3,881 |
| Service | 181 | $3,573 |
| Injection, propofol, 10 mg | 256 | $3,241 |
| Service | 187 | $1,480 |
| Short return visit (20+ min) | 29 | $1,003 |
| 2024 | 2,244 | 30 | 34 | $86,504 |
| 2023 | 2,177 | 17 | 107 | $211,656 |
| 2022 | 556 | 3 | 39 | $50,436 |
| 2021 | 3,458 | 19 | 144 | $216,693 |
| 2020 | 1,277 | 15 | 32 | $15,422 |
| 2019 | 1,349 | 18 | 35 | $46,592 |
See the largest Medicaid services in earlier years
2023
| Upper gastrointestinal endoscopy with biopsy | 205 | $51,006 |
| New patient visit (30+ min) | 721 | $46,523 |
| Service | 185 | $38,876 |
| COLONOSCOPY AND BIOPSY | 139 | $37,920 |
| Short return visit (20+ min) | 309 | $8,798 |
| DIAGNOSTIC COLONOSCOPY | 26 | $6,890 |
| Service | 179 | $6,840 |
| New patient visit (45+ min) | 54 | $4,467 |
| TISSUE EXAM BY PATHOLOGIST | 98 | $3,653 |
| OFFICE/OUTPATIENT NEW SF MDM 15 MINUTES | 62 | $2,609 |
| Return visit (30+ min) | 32 | $1,450 |
| Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 17 | $1,097 |
2022
| Clinic visit/encounter, all-inclusive | 170 | $50,399 |
| Return visit (30+ min) | 261 | $38 |
| Short return visit (20+ min) | 125 | $0 |
2021
| Clinic visit/encounter, all-inclusive | 607 | $179,488 |
| Unlisted special service, procedure or report | 100 | $12,754 |
| Upper gastrointestinal endoscopy with biopsy | 283 | $6,443 |
| Service | 119 | $5,659 |
| TISSUE EXAM BY PATHOLOGIST | 160 | $4,430 |
| Injection, propofol, 10 mg | 427 | $1,669 |
| Diagnostic upper gastrointestinal endoscopy | 30 | $1,481 |
| IP/OBS CONSLTJ NEW/EST PT MOD MDM 60 MINUTES | 67 | $1,456 |
| Service | 126 | $1,012 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 146 | $792 |
| Ringers lactate infusion, up to 1000 cc | 186 | $757 |
| PROTHROMBIN TIME | 146 | $359 |
2020
| Upper gastrointestinal endoscopy with biopsy | 212 | $4,729 |
| Unlisted special service, procedure or report | 28 | $3,667 |
| TISSUE EXAM BY PATHOLOGIST | 127 | $2,527 |
| Injection, propofol, 10 mg | 295 | $1,009 |
| Service | 43 | $929 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 170 | $601 |
| Service | 89 | $600 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 19 | $453 |
| IP/OBS CONSLTJ NEW/EST PT MOD MDM 60 MINUTES | 13 | $327 |
| PROTHROMBIN TIME | 141 | $271 |
| Ringers lactate infusion, up to 1000 cc | 79 | $189 |
| Basic metabolic panel (Calcium, ionized) This panel must include the following: Calcium, ionized (82330) Carbon dioxide (bicarbonate) (82374) Chloride (82435) Creatinine (82565) Glucose (82947) Potassium (84132) Sodium (84295) Urea Nitrogen (BUN) (84520) | 15 | $80 |
2019
| Clinic visit/encounter, all-inclusive | 187 | $35,791 |
| Service | 14 | $2,533 |
| Service | 130 | $1,950 |
| Upper gastrointestinal endoscopy with biopsy | 130 | $1,814 |
| TISSUE EXAM BY PATHOLOGIST | 104 | $1,447 |
| Injection, propofol, 10 mg | 136 | $494 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 119 | $433 |
| Service | 54 | $427 |
| Fentanyl citrate injection | 93 | $324 |
| Short return visit | 44 | $285 |
| IP/OBS CONSLTJ NEW/EST PT MOD MDM 60 MINUTES | 12 | $268 |
| Ringers lactate infusion, up to 1000 cc | 59 | $237 |
Drugs they prescribed that Part D paid
$14,823
Pharmacies billed $14,823 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 242) in 2024. At or below the middle of the specialty; the typical gastroenterology clinician is at 0%.
211 generic and 31 brand-name prescriptions · $14,823 in drug cost · 22 antibiotic prescriptions to 12 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Sod Sulf-Potass Sulf-Mag Sulf | 81 | $4,613 | $57 |
| Omeprazole | 60 | $336 | $6 |
| Gavilyte-G | 20 | $196 | $10 |
| Pantoprazole | 11 | $189 | $17 |
Year by year
| 2024 | 242 | 151 | 0% (0) | 13% | $14,823 |
| 2023 | 267 | 172 | 0% (0) | 16% | $16,011 |
| 2022 | 435 | 231 | 0% (0) | 31% | $28,296 |
| 2021 | 243 | 95 | 0% (0) | 8% | $113,722 |
| 2020 | 254 | 117 | 0% (0) | 17% | $16,857 |
| 2019 | 170 | 94 | 0% (0) | 9% | $43,684 |
| 2018 | 106 | 49 | 0% (0) | None | $15,701 |
| 2017 | 15 | None | 0% (0) | None | $3,411 |
| 2016 | 42 | 11 | 0% (0) | None | $3,586 |
| 2015 | 80 | 26 | None | 24% | $13,457 |
| 2014 | 292 | 38 | 5% (14) | 11% | $14,932 |
| 2013 | 93 | 20 | None | 16% | $3,787 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 4 drugs
| Sod Sulf-Potass Sulf-Mag Sulf | 77 | $6,099 | $79 |
| Omeprazole | 82 | $983 | $12 |
| Sucralfate | 15 | $747 | $50 |
| Gavilyte-C | 15 | $294 | $20 |
2022: 8 drugs
| Clenpiq | 34 | $5,638 | $166 |
| Suprep | 31 | $3,543 | $114 |
| Sucralfate | 32 | $2,315 | $72 |
| Omeprazole | 112 | $1,566 | $14 |
| Gavilyte-G | 64 | $1,028 | $16 |
| Peg-3350 and Electrolytes | 41 | $565 | $14 |
| Pantoprazole | 19 | $378 | $20 |
| Dicyclomine | 13 | $275 | $21 |
2021: 7 drugs
| Omeprazole | 104 | $1,674 | $16 |
| Sucralfate | 20 | $704 | $35 |
| Clarithromycin | 13 | $488 | $38 |
| Pantoprazole | 16 | $169 | $11 |
| Metronidazole | 18 | $97 | $5 |
| Amoxicillin | 11 | $96 | $9 |
| Ciprofloxacin | 14 | $52 | $4 |
2020: 8 drugs
| Sucralfate | 20 | $1,104 | $55 |
| Omeprazole | 70 | $914 | $13 |
| Gavilyte-G | 38 | $498 | $13 |
| Pantoprazole | 15 | $235 | $16 |
| Peg-3350 and Electrolytes | 18 | $220 | $12 |
| Dicyclomine | 11 | $143 | $13 |
| Levofloxacin | 15 | $84 | $6 |
| Metronidazole | 11 | $78 | $7 |
2019: 4 drugs
| Omeprazole | 50 | $793 | $16 |
| Gavilyte-G | 41 | $577 | $14 |
| Pantoprazole | 11 | $402 | $37 |
| Dicyclomine | 11 | $80 | $7 |
2018: 4 drugs
| Entecavir | 11 | $9,190 | $835 |
| Omeprazole | 20 | $255 | $13 |
| Metronidazole | 12 | $71 | $6 |
| Ciprofloxacin | 13 | $38 | $3 |
2016: 1 drug
| Omeprazole | 12 | $53 | $4 |
2015: 1 drug
| Omeprazole | 12 | $78 | $7 |
2014: 6 drugs
| Atorvastatin | 11 | $191 | $17 |
| Lisinopril | 34 | $163 | $5 |
| Metformin | 30 | $160 | $5 |
| Gabapentin | 14 | $113 | $8 |
| Hydrochlorothiazide | 25 | $103 | $4 |
| Metoprolol | 14 | $39 | $3 |
2013: 1 drug
| Lisinopril | 19 | $97 | $5 |
Money from drug and device companies
$197 in 2025
| 2025 | 4 | 9 | None | $197 |
| 2024 | 15 | 55 | None | $1,711 |
| 2023 | 6 | 21 | None | $399 |
| 2022 | 6 | 11 | None | $217 |
| 2021 | 4 | 16 | None | $420 |
| 2020 | 4 | 7 | None | $281 |
| 2019 | 7 | 26 | None | $3,167 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $92 | 4 payments
|
| Celltrion USA | Vegzelma | $36 | 2 payments
|
| Abbvie | Rinvoq | $36 | 2 payments
|
| QOL Medical | Sucraid | $32 | 1 payment
|
See all 9 published payments
| Celltrion USA | Meals · 2025-10-15 | Vegzelma | $22 |
| Celltrion USA | Meals · 2025-07-20 | Vegzelma | $15 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-05-05 | Xifaxan | $23 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-03-24 | Xifaxan | $25 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-03-03 | Xifaxan | $25 |
| Abbvie | Meals · 2025-02-05 | Rinvoq | $18 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-02-04 | Xifaxan | $20 |
| QOL Medical | Meals · 2025-01-31 | Sucraid | $32 |
| Abbvie | Meals · 2025-01-23 | Skyrizi | $17 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $1,711
| Abbvie | Rinvoq | $389 | 12 payments
|
| Ardelyx | Ibsrela | $301 | 11 payments
|
| Madrigal Pharmaceuticals | Resmetirom | $179 | 7 payments
|
| CVRx | Barostim Neo System | $169 | 1 payment
|
| Phathom Pharmaceuticals | Voquezna | $123 | 4 payments
|
| Celltrion USA | Vegzelma | $120 | 4 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $111 | 5 payments
|
| QOL Medical | Sucraid | $77 | 2 payments
|
| Janssen Biotech | Tremfya | $69 | 3 payments
|
| Boston Scientific | Autotome Rx 49 | $57 | 1 payment
|
| Echosens North America | Fibroscan | $32 | 1 payment
|
| Genzyme | Dupixent | $25 | 1 payment
|
| Intercept Pharmaceuticals | Ocaliva | $21 | 1 payment
|
| Gilead Sciences | None | $20 | 1 payment
|
| Aimmune Therapeutics | Vowst | $19 | 1 payment
|
2023: $399
| AbbVie | Linzess | $168 | 9 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $64 | 3 payments
|
| Boston Scientific | None | $48 | 2 payments
|
| Ardelyx | Ibsrela | $45 | 3 payments
|
| Regeneron Healthcare Solutions | Dupixent | $38 | 2 payments
|
| Takeda Pharmaceuticals U.S.A. | Entyvio | $36 | 2 payments
|
2022: $217
| Abbvie | Rinvoq | $92 | 4 payments
|
| Ferring Pharmaceuticals | Clenpiq | $48 | 3 payments
|
| Boston Scientific | General - Biliary Devices | $28 | 1 payment
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $24 | 1 payment
|
| Intercept Pharmaceuticals | Ocaliva | $13 | 1 payment
|
| Janssen Biotech | Remicade | $12 | 1 payment
|
2021: $420
| Boston Scientific | Exalt | $302 | 9 payments
|
| AbbVie | Mavyret | $86 | 5 payments
|
| Welch Allyn | None | $18 | 1 payment
|
| Intercept Pharmaceuticals | Ocaliva | $15 | 1 payment
|
2020: $281
| Cook Medical | Cook Medical Hemostasis | $93 | 1 payment
|
| Boston Scientific | Acquire | $91 | 2 payments
|
| AbbVie | Creon | $74 | 3 payments
|
| Intercept Pharmaceuticals | Ocaliva | $23 | 1 payment
|
2019: $3,167
| Endogastric Solutions | Esophyx | $1,085 | 4 payments
|
| Boston Scientific | Acquire | $1,042 | 11 payments
|
| Apollo Endosurgery US | Overstitch | $693 | 7 payments
|
| Micro-tech Endoscopy USA | All Products | $210 | 1 payment
|
| Gilead Sciences | Vemlidy | $98 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Amitiza | $21 | 1 payment
|
| Covidien LP | Bravo | $18 | 1 payment
|
Professional record
- NPI
- 1346554201
- Licence
- CA A118254California A118254: Current · expires 2027-09-30
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RG0100X (207RG0100X); Internal medicine (207R00000X)
- Mailing address
- 1225 Wilshire Blvd, Los Angeles, CA, 90017
- NPI first listed
- 2010-08-03
- NPI last updated
- 2023-12-26
- NPI record certified
- 2023-12-26
This is when the NPI record was last certified, not a medical board exam.